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by Marshall W. Anderson*
Introduction
Let me give a few introductory remarks and see if I
can stir up some questions. Figure 1 is a schema ofthe
multistep process of transformation of cells by chemi-
cals. There have been several versions of this during
this symposium, and this is mine. There are essentially
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FIGURE 1. Multistep transformation ofcells by chemicals.
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cess. Both of them will be a carryover of the last two
discussions we've had.
The first issue is the so-called first step of transfor-
mation, which is the formation of an initiated cell. The
formation of an initiated cell is in itself at least a two-
stepprocess, andthere aremanyotherfactorsinvolved.
It involves the damage of the DNA either directly or
indirectly by the agent. This damage is referred to as
promutagenic lesions. In order to obtain an initiated
cell, the damage must be fixed by replication.
The controversy over the for-mation ofinitiated cells
is not in the formation of DNA damage but in this fix-
ation step. How can the fixation occur? To bring this
into focus with Ray Tennant's discussion (1), whentest-
ing mutagenic chemicals with the in vitro test or the
Ames test, you obviously do not take the fixation step
into account, because the cells ofthe bacteria are divid-
ing. So if DNA is damaged, mutations are more than
likely to occur.
However, in the whole animal the fixation step itself
could be the limiting step. Jim Swenberg was kind
enough to lend me a few slides and I want to illustrate
with formaldehyde that you must take this step into
account (2).
The tumor-response curve obtained with formalde-
hyde is very nonlinear. I will avoid using the word
"threshold," but the slope here is probably approaching
zero as the dose decreases. If you look at the promu-
tagenic damage, i.e., the DNA adducts, the DNA
adduct levels are fairly linear as you go to lower doses.
Assume for purposes ofargument that it is linear. For-
get that it's formaldehyde. Thus, apparently, the for-
mationofthepromutagenic damagealoneisnotenough.
But then, as Jim Swenberg and his co-workers have
shown, the induction of cell turnover by formaldehyde
is very dose dependent. Infact, the breaks inthe tumor
curve and in the curve showing the induction of cell
turnover are similar. So at lower doses where you saw
no tumor response, there was essentially no detectable
induction of cell turnover.M. W. ANDERSON
Again, I should sayJim Swenberg has pioneered the
approach to examine cell replication in chronic admin-
istration of chemicals with carcinogenic regimens.
Obviously, from this set of data (and I think there are
similar examples) you would conclude that promuta-
genic lesions exist, but tumors are not evident because
the damage is not fixed.
This can even occur with one chemical in the same
animal, for example, with the tobacco specific nitrosa-
mine 4-(N-methyl-N-nitrosamino)-1-(3-pyridyl)-1-
butanone (NNK) (3). There are three tumor induction
sites with NNK in the Fischer rat, and they have very
different dose responses. The induction of nasal cavity
and liver tumors probably requires the induction ofcell
turnover by NNK, but apparently that is not the case
in the lungs.
Suppose a compound that is mutagenic in the Ames
tests and other short-term tests has a linear response
as far as promutagenic lesions are concerned, yet the
slope of the tumor-response curve is decreasing. This
could be a result ofthe lack ofinduction ofcell turnover
at lower doses. The question is how to regulate the
compound. Should you regulate it based on the tumor
response or based on the promutagenic lesions?
Obviously, there are pros and constoeitherstrategy.
Personally, I don't want to be walkingaround with pro-
mutagenic lesions. Several presentations during Mon-
day's session of DNA adducts reaffirm my conviction,
based on two points. Firstly, some types ofbulky DNA
adducts are very persistent in vivo. For example, Mir-
iam Poirier showed that a cisplatin adduct in humans
was present 22 months after the last therapeutic dose
(4). There are several examples ofthis. So people could
be walking around with these adducts and they might
get sick, which causes cell turnover. Thus, mutations
would result. Secondly, Phil Hanawalt's data suggests
that a given cell type only repairs the DNA damage in
the active genes of that cell (5). The transcriptionally
active genes are repaired, whereas the inactive ones
are not. What happens if a chemical binds to an onco-
gene, for example, c-mos, that is inactive in most cells?
Ifyou induce a mutation in the promoter region ofthe
gene itself, you could transform the cell. These possi-
bilities require consideration.
There is another argument concerning the promuta-
genic lesions. An increasing amount ofdata shows that
DNA damage could enterthis process in severalplaces.
For example, the transformation of a benign tumor to
a malignant tumor could result from a second-hit type
phenomenon in the benign tumor. This is shown to be
the case in the skin and liversystems, where second hit
can increase the transformation from abenign tumor to
a malignant tumor (6,7). Also, Julian Peto's data yes-
terday showed that older people exposed to radiation
were more sensitive to tumor induction than younger
people (unpublished observations). Thus, there isample
data to suggest that genotoxic lesions are also involved
in the latter stages of malignancy.
The second issue I wanted to address about the mul-
tistep process concerns compounds that do not act by
genotoxic mechanisms and are promoters but not cyto-
toxic promoters. I agree that if a compound induces
tumors only by cytotoxicity at high doses, then the
chemical is probably safe. The arguable point is how to
pickoutchemicals (e.g., 12-0-tetradecanoyl-phorbol-13-
acetate (TPA); 2,3,7,8-tetra-chlorodibenzo-p-dioxin
(TCDD); and hormonal promoters such as estrogen)
whosemode ofactionisthrough specificreceptors. How
can we protect ourselves against compounds like
TCDD? TCDD was completely negative in allgenotoxic
tests. I think at the doses administered in the bioassay
studies, TCDD was not overly cytotoxic. So how can
we identify this type of compound as having carcino-
genic properties? One possible approach was outlined
by Steve Reynolds in an earlier presentation at this
conference (8). Comparisons of activated oncogenes
between spontaneously occurring tumors and chemi-
cally induced tumors have the potential to identify non-
genotoxic, noncytotoxic chemicals. Steve outlined this
approach for the B6C3F1 mouse liver model. However,
the approach can obviously be utilized in other animal
model systems.
The following is a brief description ofthis approach.
Assume the incidence of mouse liver tumors increased
from 30% in control to 70% in treated animals. Analysis
showed that the pattern of activated oncogenes were
the same in treated and controls. In addition, a careful
analysisofcellturnoverwasdone atthedosesemployed
in the carcinogenesis study. If there was chemically
induced cell turnover at the doses employed, one could
argue that the chemical is just cytotoxically promoting
these spontaneous lesions. But suppose there was no
cytotoxicity, as with TCDD? In this case, the chemical
may be doing something very specific, like acting
through areceptor. We need to take advantage ofsome
ofthese sensitive invivo model systems to analyze indi-
vidual steps in the carcinogenesis process.
Discussion
DR. RAYMOND TENNANT, NIEHS: In terms of the
identification of tumor promoters, I think this is one
excellent way, involving the mouse, at least. As apoint
ofdeparture, I would really like to offer the possibility
that the only thing that really separates a tumor pro-
moterfrom a carcinogen is the dose rate atwhich it was
applied. I just took a quick screen out ofthe NCI data
base, the CCRIS. Inthere they list 94 substances class-
ified as tumor promoters in any system, i.e., skin or
any two-stage model system. Ofthose there have been
21 that have been assayed in a chronic type regimen,
and 14 are tumorigenic in a chronic regimen. If a sub-
stance is intrinsically carcinogenic, it seems to me that
it is irrelevant whether it can act in a two-stage pro-
motion system.
DR. JAMES SWENBERG, CHEMICAL INDUSTRY INSTI-
TUTE OF TOXICOLOGY: I'm not sure if I really caught
everythingyousaid, Ray, butgettingbacktoMarshall's
premise here, I think there probably is a good reason
to try to distinguish between the cytotoxic carcinogens
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and the others. I would guess, sitting here listening to
all three of these talks this afternoon, that if we took
some pieces out of yours, and some pieces out of Dick
Kociba's and some pieces out of Marshall Anderson's,
maybe we could put together a reasonable working
method here.
You had 73 compounds, of which about half of the
carcinogens were nonmutagenic. And Dick Kociba
showed aslidewheretwo-thirdsofthecarcinogenswere
only positive at the high dose, quoting from Joe Hase-
man. It would be very interesting to see if those two
line up with a much closer alignment. I would guess
that they do. I think that Marshall's idea ofidentifying
promoters by comparison of patterns of activated on-
cogenes between spontaneous tumors and chemically
induced tumors is a potential way to do that.
I'd like to come back to something that Marshall
raised about replication and promutagenic damage, and
bring it back to the theme ofthis conference or at least
what I understood was the theme of the conference.
How do we get basic research findings into the risk
assessment process? We really haven't dealt with that
yet at this conference. Or, at least, I haven't seen very
much that has dealt with it. There's been a great deal
of lip service paid to this issue over the last several
years, but we really don't have any methods yet that
are really doingthatjob. Maybe we don'thave the right
data yet. But it would seem to me that one ofthe issues
that we need to start addressing here is how and when
are we going to start putting mechanistic data into the
risk assessment process?
I maintain that one could put in the dose response for
cell proliferation, and one could put in what happens
with promutagenic adducts. We need to start devel-
oping those models so that this can be done. That's not
going to answer the question of promoters that you've
just raised here, but I think we can start addressing
the quantitative aspects of risk assessment if we start
incorporating some ofthe biology in the basic research.
So I guess I'd like to turn this around and ask you and
the rest ofthe audience howwe'regoingto startgetting
this data into the process.
DR. ROBERT DEDRICK, NIH: Well, I think the an-
swer is quite simple. Up until this afternoon's session,
a very large proportion of the carcinogen assessment
group from the EPA was here to listen to the presen-
tations. And I think it gets incorporated when it gets
sufficiently persuasive to get incorporated.
DR. GEORGE LUCIER, NIEHS: I'd like to raise one
other issue regarding initiation promotion. I want to
use an example ofestrogencarcinogenicityinthe Syrian
hamster model. When you give diethylstilbestrol to a
Syrian hamster, it gets kidney tumors. When you give
estradiol, which is structurally divergent (remember
John McLachlan's talk) from DES, this also gives the
same high incidence ofkidney tumors.
Kurt Randerath looked at the DNA adducts in the
kidney after chronic exposure to these compounds and
found that in both cases DNA adducts were detected
by the postlabeling procedure. The interesting thing
wasthattheadductswerethe sameinbothcases, which
means that they weren't arising from the estrogens.
They were arising from estrogen-mediated influences
on either dietary constituents or endogenous factors
resulting in the formation of them. But, nevertheless,
these might be promutagenic lesions. They might be
involved in the carcinogenic process.
So in this case would you call those estrogens geno-
toxicornotgenotoxic? Toputitinyourwords, itdoesn't
make any difference to me whether I'm walking around
with adducts that arose from a hormone or a dietary
constituent than exposure to the chemical. So how
would you classify that chemical as an initiator or a
promoter?
DR. ANDERSON: Until you know more about the
structure of the adducts I'm not sure you can answer
that question.
DR. LUCIER: You're absolutely right. I don't think
youcanevalutetherole oftheadductinthecarcinogenic
process until you know what the structure is and
whether it's on a hot spot and so forth. But I think it
was clearthat because ofthe structural divergence that
you're really not dealing with adduct formation from
the estrogens themselves. So it raises a question ofhow
do you call that? I mean, it's a carcinogen and the ad-
ducts may be involved. You have evidence that the ad-
ducts might be involved even though they, themselves,
wouldn't be formed fromthose structures. That's some-
what ofa dilemma. And I think it's appropriate for this
kind ofdiscussion ifwe're talking about classifying car-
cinogensaccordingtostages. SoitcouldbethatifTCDD
did the same thingin your model forthe oncogenes that
it'd be producing indirect adduction, then you may not
get the same genetic lesions in the activated oncogenes
as seen in the spontaneously occurring tumors. So it's
an additional complexity, and I don't know how to deal
with it if one is going to use initiation-promotion in the
risk assessment process.
DR. ANDERSON: You would surely have to call the
chemical genotoxic if it really is forming the adduct
itself, or indirectly. I think the point Jim was making
was valid. I think he's been trying to do it, and we have
too. The product of adducts times cell replication is
surely a much better dose term to use in low dose ex-
trapolation ofcarcinogenic data. As far as low dose ex-
trapolation ofthe carcinogenic data in rodents forgeno-
toxicchemicals, that'sobviouslythewaytodoit. Ithink
we've clearly shown that. Another question that I was
raising is should society regulate promutagenic lesions
themselves and notthecarcinogenic data? Ibelieve that
this is a valid consideration.
UNKNOWN SPEAKER: Marshall, I just wanted to
make a quick comment. I agree with everything you
said about those mutations at the 13th and the 117th
with the proviso, and I think you would agree too, that
we have to learn more about the potential genotoxicity
aside from the negative Salmonella.
The other thing I didn't hear a comment on was the
original dilemmayouposed aboutformaldehyde. I don't
recall the first slide, but I thought the formaldehyde
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data indicated a less than linear response for DNA le-
sions as the dose decreases. And maybe that might give
you a little comfort to appreciate Jim's view that with
some chemicals you do have increased efficiency at low
dose. I don'tknowifthatwillhelpyouhavesome degree
ofcomfort ifit turns out that the numberofadducts are
somewhat less than linear.
DR. SWENBERG: Let me just address that, because
I don't think it came across real clearly from the slides.
What you have in that slide was covalent bindings di-
vided by exposure parts per million. So that it has a
linear phase at the low end and a linear phase at the
high end and a nonlinear portion in between there. And
I think Marshall didn't get it quite right. Because the
point was that it's linear at the high end. At 6 and at
15 ppm you have linear covalent binding, but you have
a very nonlinear tumor response. And the only expla-
nation that I can come up with is cell proliferation. I
think it's a very reasonable one from a science stand-
point. There's another point that needs to be made on
yourpromutagenic adductissue. We allmustremember
that all adducts are not created equal. They don't have
equal potency, they don't have equal half-times, and
they differ in different cell types and different tissues.
The examples range from 06-methylguanine, which
ends up being persistent in brain at about 10% at the
highest dose for 6 months. The cisplatin that you re-
ferred to. We have other adducts. We could take 06_
methylguanine in the liver, and it's virtually all re-
paired. It's first order, so there's always going to be a
little something left over. We're not going to get rid of
it all. And we have to bring in the efficiency for causing
mispairing and the time thatthese adducts hangaround
in the tissues that they're causing the tumors in. It's a
far more complex thing. And then you get into site-
specific mutagenesis. So as I said, we've got a tremen-
dous way to go before we're everthere completely. But
I think we already have enough data that we can start.
And that's what I would encourage.
DR. Roy ALBERT, UNIVERSITY OF CINCINNATI
MEDICAL CENTER: I think, fundamentally, as I said at
the beginning of the discussion the first day, it is an-
ticonstructive to continue to try to view the process of
carcinogenesis in an initiation-promotion framework. I
think we should not only not regulate on that basis; we
shouldn't evennecessarily eventhinkonthatbasis. And
TCDDisboththebestandworstofallexamplesbecause
it is one ofthe most potent carcinogens that we've seen.
It not only promotes spontaneously occurring tumors,
but it induces uncommon tumors. TCDD's lesions in
DNA obviously occur, because Bill Greenlee presented
results here that showed that you alter the differentia-
tion pattern ofhuman keratinocytes. We know that it's
a potent inducer of enzymes. It causes essentially ir-
reversible enzyme activation or deregulation. And
there's a known sequence 5' to the Ah locus in human
cells that is specifically responsive to a TCDD ligand
complex. It obviously is genotoxic. It changes pheno-
types heritably, but it's not mutagenic. It certainly is
a promoter because it acts in a two-stage system, but
it's carcinogenic when you administer it in a chronic
regimen.
I think TCDD is an example of why the two-stage
conception is not universally valid. That's why you can
get an activated ras out ofTCDD potentially that won't
involve either a 61st or a 118th codon mutation. It may
well nonmutagenically activate the ras gene simply
through the growth factor linkage. You're heritably al-
tering phenotypes.
DR. ANDERSON: Can Julian have a shot?
DR. JULIAN PETO, ROYAL CANCER HOSPITAL, ENG-
LAND: I said this yesterday, and it's been said at every
risk assessment meeting I've been to for a thousand
years. Is anybody even prepared to defend the use of
theterm "promoter"? I knoweverybodykeeps standing
up and sayingthat it'sridiculous. But I meanis anybody
here-are there representatives of EPA here? Who's
prepared to defend its use in risk assessment? Because
it obviously is completely contradictory and silly. I
mean, everybody who has spoken as a scientist on risk
assessment has pointed it out at every level.
DR. ANDERSON: But the point is that it surely has
meaning mechanistically. Cells that have alterations
like activated ras or neu or other oncogenes respond
differently thannormalcellstoagentslikeTCDD, phen-
obarbital, etc., that will selectively give growth advan-
tage either in a negative sense or a positive sense to
this cellthat already has a change in it. Fromthat sense
it makes sense to differentiate between the two. I think
Ray's example of TCDD is really not good. Because I
think we're all walking around, not just the B5 mouse,
with initiated cells sitting there waiting for something
to be done. I think your data shows that with the ra-
diation. Now whether you want to regulate it, whether
you want to call it a carcinogen, I don't know. But me-
chanistically it makes sense. And I think the oncogene
story drives it home if you look at the data in totality.
DR. PETO: But the point is-it's obviously right, I
mean the stuff that Henry Pitot showed and the stuff
thatyou're showingin the epidemiology. It's quite clear
that you're interacting with things that are going on
anyway spontaneously. Therefore, anything that acts
at any stage is a complete carcinogen. I mean, the word
"complete carcinogen" doesn't have any meaning.
DR. ANDERSON: I didn't use that term.
DR. PETO: That's the point. That's why for risk as-
sessment purposes to make the distinction is silly and
dangerous. I've shown radiation as a promoter. So it
doesn't mean that you don't have to worry about it as
much as if it was an initiator.
DR. ANDERSON: Why have you shown it's a pro-
moter?
DR. PETO: Quite clearly it's a late stage action.
DR. ANDERSON: But it might be active genotoxically
in that stage.
DR. PETO: Doesn't "promoter" mean a nongenotoxic
carcinogen? Whatisthe definition ofapromoter? I don't
know what the definition is.
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DR. ANDERSON: Well, to me it's an agent that selec-
tively causes a clonal expansion of a certain cell type.
DR. PETO: Okay, but that's a totally different mean-
ing. Is that what's happening there? Is that what ra-
diation is doing?
DR. ALBERT: I think that the excitement about pro-
moters in carcinogenesis from the risk assessment
standpoint is that those agents that interact through
cellreceptormechanisms give the promise ofbeingable
to define low-level dose response, which from a mecha-
nistic standpoint in a way which contrast between a
single molecule, single hit, process that we're essen-
tially locked into.
The other comment I'd like to make is that although
the interaction between adduct levels and cell prolif-
eration makes a beautiful story, I think there ought to
be some reservations about the extent to which it's ap-
plicable to different systems. We'vejust got some pilot
data. Admittedly, it's pilot data. But the chronic appli-
cation ofbenzo[a]pyrene to the mouse skin up through
the time of tumor formation, which begins at about 7
months, so that the exposures are quite substantial,
doesn't produce any detectable change in the cell turn-
over rate.
Now, to be sure, the skin has an inherent turnover
rate, but it raises the question as to whether there is
necessarily a quantitative relationship between cellpro-
liferation and adducts that can explain the time and
magnitude of tumor response. It may be yes, but I've
found that result to be kind of a bucket of cold water.
DR. ANDERSON: But you couldn't induce tumors with
just one single dose at that low-dose level. You had to
give it repeatedly. So the probability of having a cell
undergoing replication greatly increases.
DR. SWENBERG: I didn't get it all down because I
couldn't write fast enough, but Henry Pitot gave us the
definition ofa promoter that was accepted at the recent
promotion meeting. It had two aspects to it: reversible
expansion of initiated cells and/or reversible alteration
ofgenetic expression. And Julian said we didn't have a
definition ofit. That was the definition that was given.
I didn't hear anybody counter it at the time. It's a rea-
sonable definition that we can start working from.
DR. ANDERSON: That's a good place to end, Jim.
DR. SWENBERG: One last comment for Roy. You
know, this business of being locked into one hit, one
molecule, there is no evidence to support that. No evi-
dence at all. It's all dogma.
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